EV Nickel Inc. | WebDisclosure

Basculer en Français

8616	Companies
142275	Keywords
78104	Articles
76024	Press releases

Home
Companies
EV Nickel Inc.

BRIEF

published on 08/16/2024 at 10:46, 7 months 30 days ago

First Berlin Equity Research réaffirme la note d'ACHAT pour APONTIS PHARMA AG

APONTIS PHARMA AG Recommandation D'achat Première Recherche Sur Les Actions À Berlin Résultats H1/24 Entreprise De Pilules Individuelles
BRIEF

published on 08/16/2024 at 10:46, 7 months 30 days ago

First Berlin Equity Research Reaffirms BUY Rating for APONTIS PHARMA AG

First Berlin Equity Research Buy Recommendation APONTIS PHARMA AG H1/24 Results Single Pill Business
PRESS RELEASE

published on 08/16/2024 at 10:41, 7 months 30 days ago

Original-Research: APONTIS PHARMA AG (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research recommends buying APONTIS PHARMA AG shares with a target price of €17 after solid H1/24 results and positive outlook. Analyst Christian Orquera maintains his BUY rating

First Berlin Equity Research Buy Recommendation APONTIS PHARMA AG H1/24 Results Christian Orquera
PRESS RELEASE

published on 08/12/2024 at 18:16, 8 months 3 days ago

Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
Montega AG stuft APONTIS PHARMA AG mit Kaufempfehlung und Kursziel von 16,50 EUR. APONTIS PHARMA zeigt solide Q2-Entwicklung und ermutigende Erfolge in neuer Vertriebsstrategie

Montega AG Kaufempfehlung APONTIS PHARMA AG Kursziel 16,50 EUR Solide Entwicklung
BRIEF

published on 08/09/2024 at 07:35, 8 months 6 days ago

APONTIS PHARMA annonce une forte croissance au premier semestre 2024

APONTIS PHARMA Croissance Des Revenus Amélioration De L'EBITDA Combinaisons De Pilules Simples Coopération Avec Novartis
BRIEF

published on 08/09/2024 at 07:35, 8 months 6 days ago

APONTIS PHARMA Reports Strong Half-Year Growth in 2024

Revenue Growth APONTIS PHARMA Single Pill Combinations EBITDA Improvement Novartis Cooperation
PRESS RELEASE

published on 08/09/2024 at 07:30, 8 months 6 days ago

APONTIS PHARMA with profitable revenue growth for Single Pill combinations in the first half of 2024 – forecast for the full year confirmed
APONTIS PHARMA reports profitable revenue growth with Single Pill combinations in the first half of 2024. Forecast for full year 2024 confirmed. Earnings and sales improvements noted

EBITDA Revenue Growth Forecast APONTIS PHARMA Single Pill Combinations
BRIEF

published on 06/27/2024 at 07:35, 9 months 18 days ago

APONTIS PHARMA AG Appoints CFO Thomas Zimmermann to Management Board

Management Board APONTIS PHARMA ESG Strategy Thomas Zimmermann Single Pill
BRIEF

published on 06/27/2024 at 07:35, 9 months 18 days ago

APONTIS PHARMA AG nomme le directeur financier Thomas Zimmermann au conseil d'administration

Conseil D'administration Stratégie ESG PHARMA APONTIS Thomas Zimmermann Pilule Unique
PRESS RELEASE

published on 06/27/2024 at 07:30, 9 months 18 days ago

APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board to enhance strategic development, internationalization, and ESG strategy. CFO brings strong financial expertise

CFO Strategic Development Management Board APONTIS PHARMA AG Thomas Zimmermann

Accesswire

Published on 04/16/2025 at 02:25, 2 hours 30 minutes ago

New High-Grade Assays Extend Tolmer Silver & Gold Zones
Published on 04/15/2025 at 23:40, 5 hours 15 minutes ago

Electric Metals Announces Business Consulting Services Agreement With Terrella Capital
Published on 04/15/2025 at 23:30, 5 hours 25 minutes ago

GameSquare Holdings Reports 2024 Full Year Results
Published on 04/15/2025 at 23:30, 5 hours 25 minutes ago

AIML Announces Closing of Oversubscribed Private Placement
Published on 04/15/2025 at 23:00, 5 hours 55 minutes ago

Cerrado Gold Announces Q1 2025 Production Results At Its Minera Don Nicolas Mine In Argentina

View all ACCESSWIRE

EQS Group

Published on 04/15/2025 at 23:54, 5 hours 1 minute ago

EQS-Adhoc: DATAGROUP enters into an Investment Agreement with and supports a public purchase offer of KKR at a price of EUR 54.00 per share in cash
Published on 04/15/2025 at 21:51, 7 hours 3 minutes ago

EQS-Adhoc: Adtran Networks SE updates preliminary results for the financial year 2024
Published on 04/15/2025 at 18:53, 10 hours 1 minute ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/15/2025 at 18:30, 10 hours 25 minutes ago

GURIT REPORTS NET SALES OF CHF 85.2 MILLION IN THE FIRST QUARTER OF 2025; ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS
Published on 04/15/2025 at 18:00, 10 hours 55 minutes ago

ALTHEORA: RESILIENCE DES RESULTATS ANNUELS 2024

Les Echos

Published on 04/15/2025 at 19:00, 9 hours 55 minutes ago

Covivio Hotels - Descriptif du programme de rachat d’actions autorisé par l’Assemblée Générale Mixte des actionnaires du 15 avril 2025
Published on 04/15/2025 at 18:00, 10 hours 55 minutes ago

NFL Biosciences annonce la mise à disposition de son rapport financier annuel 2024
Published on 04/15/2025 at 18:00, 10 hours 55 minutes ago

Covivio Hotels - Revenus à fin mars 2025 : la croissance se poursuit
Published on 04/15/2025 at 18:00, 10 hours 55 minutes ago

Covivio Hotels - Revenues at end-March 2025: continued growth
Published on 04/15/2025 at 17:45, 11 hours 10 minutes ago

DAMARTEX / Droits de vote bruts et réels au 31 mars 2025

View all LES ECHOS COMFI WIRE